NIH-sponsored trial data offers further evidence to help inform mpox treatment decisions.

The antiviral drug tecovirimat used without other antivirals did not reduce the time to clinical resolution of clade II mpox ...

A NIH-led trial found tecovirimat ineffective in reducing mpox lesion healing time or pain relief. The study was halted in 2024, with findings presented at CROI 2025.

The current standard treatment for mpox is an antiviral medication known as tecovirimat, but it’s not always used. “Most people do not need treatment for monkeypox,” Adalja says.

Tecovirimat is the drug most commonly used to treat patients infected with the mpox virus. Unfortunately, it is sometimes ineffective against certain variants of the virus that have mutations in ...

The results from STOMP reinforce the value of randomized clinical trials during outbreaks of infectious diseases, like mpox,” said Past ACTG Chair Judith Currier M.D., M.Sc. “There was considerable ...

Two hundred and fifteen cases of mpox infection were reported to Santé publique France in 2024. Tecovirimat is the drug most commonly used to treat patients infected with the mpox virus. Unfortunately ...

Tecovirimat 200mg/vial; soln for IV infusion after dilution; contains hydroxypropyl-β-cyclodextrin. Store Tpoxx injection in a refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze.

Tecovirimat is the drug most commonly used to treat patients infected with the mpox virus. Unfortunately, it is sometimes ineffective against certain variants of the virus that have mutations in ...

The antiviral drug tecovirimat used without other antivirals did not reduce the time to clinical resolution of clade II mpox ...

The antiviral drug tecovirimat used without other antivirals did not reduce the time to clinical resolution of clade II mpox lesions or improve ...